OBJECTIVE: The neuropeptide Y (NPY) signal peptide polymorphism T1128C has been linked to several risk factors for cardiovascular disease. The aim of the present study was to evaluate the significance of this polymorphism for cardiovascular and cerebrovascular disease outcome. DESIGN: In a prospective study cohort, 1032 hypertensive patients (174 myocardial infarction and 170 stroke patients and 688 matched controls) were analysed for the T1128C polymorphism in the NPY gene. METHODS: The dynamic allele specific hybridization (DASH) method was used for genotyping. Serum from the same participants was analysed for total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and triglycerides. RESULTS: The frequency of the NPY T1128C polymorphism was 8.4% among patients with a myocardial infarction or stroke, as compared to 5.1% in the control group (P = 0.040). The difference remained significant after adjustment for the cardiovascular risk factors age, sex, smoking status, body mass index, systolic and diastolic blood pressure, presence of diabetes, total cholesterol, HDL, LDL and triglycerides. CONCLUSIONS: The present study indicates that the NPY T1128C polymorphism is an independent predictor for myocardial infarction and stroke in a Swedish hypertensive population.
OBJECTIVE: The neuropeptide Y (NPY) signal peptide polymorphism T1128C has been linked to several risk factors for cardiovascular disease. The aim of the present study was to evaluate the significance of this polymorphism for cardiovascular and cerebrovascular disease outcome. DESIGN: In a prospective study cohort, 1032 hypertensivepatients (174 myocardial infarction and 170 strokepatients and 688 matched controls) were analysed for the T1128C polymorphism in the NPY gene. METHODS: The dynamic allele specific hybridization (DASH) method was used for genotyping. Serum from the same participants was analysed for total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and triglycerides. RESULTS: The frequency of the NPYT1128C polymorphism was 8.4% among patients with a myocardial infarction or stroke, as compared to 5.1% in the control group (P = 0.040). The difference remained significant after adjustment for the cardiovascular risk factors age, sex, smoking status, body mass index, systolic and diastolic blood pressure, presence of diabetes, total cholesterol, HDL, LDL and triglycerides. CONCLUSIONS: The present study indicates that the NPYT1128C polymorphism is an independent predictor for myocardial infarction and stroke in a Swedish hypertensive population.
Authors: Nora Franceschini; Jean W MacCluer; Kathreen M Rose; Sue Rutherford; Shelley A Cole; Sandy Laston; Harald H H Göring; Vincent P Diego; Mary J Roman; Elisa T Lee; Lyle G Best; Barbara V Howard; Richard R Fabsitz; Kari E North Journal: Am J Hypertens Date: 2008-01-10 Impact factor: 2.689
Authors: H Kölsch; D Lütjohann; F Jessen; H Urbach; K von Bergmann; W Maier; R Heun Journal: J Neural Transm (Vienna) Date: 2005-06-15 Impact factor: 3.575
Authors: Suvi T Ruohonen; Ken Abe; Mia Kero; Laura Toukola; Saku Ruohonen; Matias Röyttä; Markku Koulu; Ullamari Pesonen; Zofia Zukowska; Eriika Savontaus Journal: Peptides Date: 2008-12-24 Impact factor: 3.750
Authors: Mi Mi Ko; Byoung Kab Kang; Ji Hye Lim; Myeong Soo Lee; Min Ho Cha Journal: Evid Based Complement Alternat Med Date: 2011-10-29 Impact factor: 2.629
Authors: Svati H Shah; Neil J Freedman; Lisheng Zhang; David R Crosslin; David H Stone; Carol Haynes; Jessica Johnson; Sarah Nelson; Liyong Wang; Jessica J Connelly; Michael Muehlbauer; Geoffrey S Ginsburg; David C Crossman; Christopher J H Jones; Jeffery Vance; Michael H Sketch; Christopher B Granger; Christopher B Newgard; Simon G Gregory; Pascal J Goldschmidt-Clermont; William E Kraus; Elizabeth R Hauser Journal: PLoS Genet Date: 2009-01-02 Impact factor: 5.917